|
|
|
市場調査レポート
腎疾患治療：製品と治療法
Renal Disease Treatments: Products and Therapies
| 発行 |
BCC Research |
| 出版日 |
2009年11月 |
商品コード |
104803 |
| ページ情報 |
英文 187 pages |
| 価格 |
|
|
Abstract
THIS REPORT
Forecasts for the U.S. market in products and services, providing data for
2008 and estimates for 2009, and projections for the market and compound
annual growth rates (CAGRs) from 2009 to 2014 Focus on pharmaceutical
products, dialysis therapies, and surgical procedures in the U.S. market for
renal failure treatment Breakdown of the dialysis equipment market by type and
manufacturer, and the dialysis services market by provider Detailed company
profiles
STUDY GOAL AND OBJECTIVES
This BCC Research market opportunity study provides an in-depth analysis of
the market for kidney failure treatment products and services, forecasting
growth and trends in the various sectors over the next 5 years. Products and
services will include those for treating acute renal failure, chronic renal
failure, and end-stage renal disease, the final phase of chronic kidney
failure. Market sectors to be covered in this report include pharmaceuticals
used to address the conditions associated with kidney failure (i.e.,
hypertension, diabetes, and anemia); hemodialysis and peritoneal dialysis
products and services; and surgical procedures used to keep the end-stage
kidney patient alive (i.e., surgeries to create vascular access sites for
dialysis, and kidney transplantation). The conclusions are illustrated with
important statistical and analytical information on markets, industry
structure and dynamics, as well as technological developments.
REASONS FOR DOING THE STUDY
Kidney failure is the ninth-leading cause of death in the U.S., accounting for
about 85,000 fatalities each year. Approximately 27 million Americans
currently have chronic kidney disease, while another 20 million are at
increased risk for developing chronic kidney disease. More than 500,000
individuals currently are being treated for kidney failure via dialysis or
kidney transplant. Nearly 400,000 individuals receive dialysis treatments
three or more times each week. Over the last decade, the chronic kidney
disease rate has risen more than 25%. During the past 5 years, the number of
new patients with kidney failure has averaged 90,000 to more than 100,000
annually.
In addition to the individuals struggling with chronic kidney disease, more
than 200,000 people suffer acute renal failure in the U.S. each year. The rate
of ARF diagnosis as a percentage of all kidney failure hospitalizations rose
from 7.3% in 1980 to 60% in 2005. Experts note that some of the increase may
be due to changes in the definition of acute renal failure. Many of these
patients acquire the condition while already hospitalized for other problems.
While sometimes temporary and reversible, acute renal failure also may lead to
chronic kidney failure. The total annual cost of treating end-stage renal
disease caused by either chronic kidney disease or acute renal failure is in
the tens of billions of dollars each year. Much of the care for chronic kidney
disease and end-stage renal disease is provided in the outpatient setting;
however, the number of hospitalizations for acute renal failure and chronic
kidney failure is substantial.
Over the past 20 years, both the numbers and rates of kidney disease hospital
discharges have increased, especially among adults age 65 years or older. In
addition, a shift has occurred for reported hospitalizations in the type of
kidney disease, from chronic to acute renal failure. An increasing number of
kidney disease hospitalizations also are associated with a concomitant
diagnosis of diabetes mellitus or hypertension. For both acute and chronic
conditions, and outpatient or in-hospital settings, nearly all of these kidney
problems require some sort of intervention, whether pharmaceutical,
mechanical, and/or surgical. This report details the various products and
services used to address renal failure. Three categories of treatment are most
prevalent: prescription medications, dialysis (hemodialysis, peritoneal
dialysis, and continuous renal replacement therapy), and surgical
intervention, which are often used in combination to treat a single case of
renal failure.
INTENDED AUDIENCE
This study aims to provide those interested in investment, acquisition, or
expansion into the renal failure treatment market with specific, detailed
information crucial to making informed decisions. Senior marketing personnel,
venture capitalists, executive planners, and research directors should find
the report of value. Readers who simply wish to understand how regulations,
market pressures, and technology interact in the renal failure treatment
industry also will find the study worthwhile.
SCOPE OF REPORT
Five-year projections for market activity and value are provided. Treatment
types and trends for acute and chronic renal failure, pricing considerations
for medications, dialysis products (dialysis machines, dialysates and
dialyzers) and therapies, and surgical procedures; companies, industry
structure and participating companies are included in the study. Not included
in the study are market analyses for water treatment systems used in making
dialysate solutions, or lower-cost dialysis supplies such as fistula needles,
bloodlines, topical anesthetics, wipes, bandages, dressings, etc. Diagnostics,
testing, and other lab services are not included, nor are training sessions
for home hemodialysis or peritoneal dialysis. For hospitalizations related to
acute renal failure and vascular access maintenance, therapy/surgical costs
reflect, as much as possible, only those expenses directly related to kidney
care. Charges for the stay in intensive care, ventilation, laboratory
services, and drugs not directly related to renal failure treatment are not
included. Ambulance costs, nursing home expenses, and non-nephrology-related
physician fees also are excluded.
INFORMATION SOURCES
Research for this report began with an in-depth analysis of technical and
business literature, as well as a review of the history of the technology.
Information from industry experts, company representatives, government
researchers, and university scientists provided the basis for an assessment of
the industry. Specific information sources include company annual reports, the
Centers for Disease Control and Prevention, U.S. Renal System Database,
National Kidney Foundation, Organ Procurement and Transplantation Network,
Network 13, National Institute of Diabetes and Digestive and Kidney Diseases
of the National Institutes of Health, National Kidney Disease Education
Program, product literature from pharmaceutical and equipment manufacturers,
scientific journals, and patent searches.
The study is divided into key chapters dealing with the three types of
interventions used in treating kidney failure: medication, dialysis, and
surgery. The report makes projections for each market in terms of constant
2009 dollars. Historical values are presented for the given year, with focus
on the U.S. market. Overseas activity is mentioned briefly in order to put the
U.S. market into a global context.
ANALYST CREDENTIALS
During the past 13 years, Susan Hanft has authored more than 14 BCC market
opportunity reports in the fields of membrane technology, medical devices,
water and wastewater treatment, and bioenergy.
Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary 4
- STUDY GOAL AND OBJECTIVES 1
- REASONS FOR DOING THE STUDY 1
- INTENDED AUDIENCE 2
- SCOPE OF REPORT 2
- INFORMATION SOURCES 3
- ANALYST CREDENTIALS 3
- RELATED BCC REPORTS 3
- BCC ONLINE SERVICES 4
- DISCLAIMER 4
Chapter-2: SUMMARY 3
- SUMMARY 5
- SUMMARY TABLE THE U.S. MARKET FOR RENAL FAILURE TREATMENT, THROUGH 2014 ($
MILLIONS) 6
- SUMMARY FIGURE U.S. MARKET FOR RENAL FAILURE TREATMENT, 1996 - 2014 ($
MILLIONS) 7
Chapter-3: OVERVIEW 12
- KIDNEY FUNCTION 8
- KIDNEY DISEASE 9
- TABLE 1 DISEASES LEADING TO RENAL FAILURE 10
- DETECTING KIDNEY DISEASE 10
- TYPICAL TESTS 10
- PATIENT POPULATIONS 11
- TABLE 2 ESTIMATED ARF, CKD, AND ESRD POPULATIONS, INCLUDING TRANSPLANT
RECIPIENTS AND ROUTINE DIALYSIS PATIENTS, 1996-2009 12
- FIGURE 1 ESTIMATED ARF, CKD, AND ESRD POPULATIONS, INCLUDING TRANSPLANT
RECIPIENTS AND ROUTINE DIALYSIS PATIENTS, 1996-2009 12
- HOSPITALIZATIONS WITH RENAL FAILURE LISTED AS A DIAGNOSIS 12
- FIGURE 2 AGE-SPECIFIC HOSPITALIZATION RATES* FOR KIDNEY DISEASE,†
BY AGE GROUP -- NATIONAL HOSPITAL DISCHARGE SURVEY, UNITED STATES, 1980-2005 13
- FIGURE 3 AGE-ADJUSTED HOSPITALIZATION RATES FOR KIDNEY DISEASE BY TYPE,
1980-2005 14
- TABLE 3 NUMBER OF HOSPITALIZATIONS AND AGE-ADJUSTED HOSPITALIZATION RATES
FOR KIDNEY DISEASE, BY SEX AND YEAR, NATIONAL HOSPITAL DISCHARGE SURVEY, 1980
- 2005 15
- FIGURE 4 NUMBER OF HOSPITALIZATIONS FOR KIDNEY DISEASE, BY SEX AND YEAR,
NATIONAL HOSPITAL DISCHARGE SURVEY, 1980 - 2005 16
- WHO PAYS THE COSTS OF KIDNEY DISEASE? 16
- WHAT MEDICARE COVERS 17
- MEDICARE' S ESRD PROGRAM 18
- Breakdown of ESRD Population by Payer 19
Chapter-4: ACUTE KIDNEY FAILURE 11
- INCIDENCE OF CHRONIC KIDNEY FAILURE 31
- CAUSES OF CHRONIC KIDNEY FAILURE 31
- TABLE 6 PRIMARY CAUSES OF KIDNEY FAILURE (% OF PATIENTS) 32
- FIGURE 7 PRIMARY CAUSES OF KIDNEY FAILURE (% OF PATIENTS) 33
- FIGURE 8 CKD PREDICTORS IN THE U.S. POPULATION AGED 20 AND OLDER 34
- CKD STAGES 34
- TABLE 7 STAGES OF CHRONIC KIDNEY DISEASE 35
- STAGE 1 35
- STAGE 2 35
- STAGE 3 36
- STAGE 4 36
- STAGE 5 (ESRD) 36
- NUMBER OF INDIVIDUALS WITH CKD 37
- TABLE 8 PATIENTS WITH CKD AND AWARENESS OF THE DISEASE, BY STAGE, 2009
(NUMBER AND %) 37
- FIGURE 9 PATIENTS WITH CKD AND AWARENESS OF THE DISEASE, BY STAGE 2009 (%)
37
- CHARACTERISTICS OF THE CKD PATIENT POPULATION 38
- TABLE 9 CKD PATIENT CHARACTERISTICS (COLUMN %) 38
- TREATMENT GOALS 38
- ESRD 39
- TABLE 10 ESRD TREATMENT, BY MODALITY (PERCENTAGE AND NUMBER OF PATIENTS) 40
- FIGURE 10 ESRD TREATMENT, BY MODALITY (PERCENTAGE OF PATIENTS) 40
- TABLE 11 DIALYSIS FOR ESRD, BY TREATMENT MODALITY, 2009 41
- FIGURE 11 DIALYSIS FOR ESRD, BY TREATMENT MODALITY, 2009 (%) 41
- COSTS OF CHRONIC KIDNEY DISEASE 41
- TABLE 12 INPATIENT/OUTPATIENT AND PHYSICIAN /SUPPLIER NET COSTS FOR CKD
($, PER PATIENT PER MONTH, 2006) 42
- TABLE 12 (CONTINUED) 43
- FIGURE 12 PPPM EXPENDITURES FOR CKD PATIENTS, 1993 - 2006 (MEDICARE,
MEDICARE/MEDICAID, MEDSTAT [EMPLOYER PAID INSURANCE]) 44
- THE U.S. MARKET FOR TREATING CHRONIC KIDNEY FAILURE AND END-STAGE RENAL
DISEASE 45
- TABLE 13 THE U.S. MARKET FOR CKD/ESRD TREATMENT BY TYPE, 1996 - 2014 ($
MILLION) 46
- FIGURE 13 THE U.S. MARKET FOR CHRONIC RENAL FAILURE TREATMENT BY TYPE,
1996-2014 ($ MILLION) 46
Chapter-5: CHRONIC KIDNEY FAILURE 16
Chapter-6: PHARMACEUTICALS USED IN RENAL FAILURE TREATMENT 33
- HEMODIALYSIS 80
- THE HEMODIALYSIS SYSTEM 80
- TABLE 33 HEMODIALYSIS SYSTEM MARKET SHARE BY MAUFACTURER, 2009 (%) 81
- FIGURE 15 HEMODIALYSIS SYSTEM MARKET BY MAUFACTURER, 2009 (%) 81
- ACUTE CARE DIALYSIS EQUIPMENT 82
- TABLE 34 THE CRRT SYSTEM MARKET BY MANUACTURER, 2009 82
- TABLE 35 DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT) 83
- DIALYZERS 83
- TABLE 36 DIALYZER PRODUCTS, MANUFACTURERS, MATERIAL, AND TYPE 84
- HEMOFILTERS 84
- TABLE 37 HEMODIALYZERS, HEMOFILTERS MARKET SHARE, 2009 (%) 85
- FIGURE 16 HEMODIALYZERS, HEMOFILTERS MARKET SHARE, 2009 (%) 85
- MODES OF HEMODIALYSIS 86
- Hemofiltration 86
- Hemodiafiltration 86
- Hemodiafiltration (Continued) 87
- FIGURE 17 INTERMITTENT RENAL THERAPIES 88
- MEASURING DIALYZER PERFORMANCE 89
- DIALYZER REUSE 89
- DIALYSATE 90
- Sodium Citrate-Containing Dialysate 91
- TABLE 38 DIALYSATE PRODUCTS FOR HD, PD, AND CRRT 91
- TABLE 38 (CONTINUED) 92
- TABLE 39 DIALYSATE MARKET BY MANUFACTURER RANK, 2009 92
- DIALYSIS EQUIPMENT COSTS 92
- TABLE 40 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD, CRRT ($) 93
- THE U.S. MARKET FOR DIALYSIS SYSTEMS AND MAJOR CONSUMABLES 93
- DIALYSIS MACHINES 93
- TABLE 41 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2014 ($
MILLION) 94
- FIGURE 18 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, 1996-2014 ($
MILLION) 95
- CONSUMABLES 95
- TABLE 42 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH
2014 ($ MILLION) 96
- FIGURE 18 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, 1996 -
2014 ($ MILLION) 96
- Dialyzers 96
- Dialysate 97
- PERITONEAL DIALYSIS 98
- MODES OF PERITONEAL DIALYSIS 99
- Continuous Ambulatory Peritoneal Dialysis 99
- FIGURE 19 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 100
- Continuous Cycler-Assisted Peritoneal Dialysis 100
- Nocturnal Intermittent Peritoneal Dialysis 101
- Tidal Peritoneal Dialysis 101
- Dialysate for PD 102
- PERITONEAL DIALYSIS EQUIPMENT MANUFACTURERS 102
- TABLE 43 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER 102
- TABLE 44 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY TYPE, 2009 (%) 103
- FIGURE 20 PERITONEAL DIALYSIS EQUIPMENT MARKET BY TYPE, 2009 (%) 103
- TABLE 45 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2009
(%) 104
- FIGURE 21 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2009
(%) 104
- CONTINUOUS RENAL REPLACEMENT THERAPIES 104
- SCUF 105
- CVVH 105
- CVVHD 105
- CVVHD (Continued) 106
- FIGURE 22 CONTINUOUS RENAL THERAPIES (SCUF, CVVD, CVVHD) 107
- CVVHDF 108
- FIGURE 23 CONTINUOUS VENO-VENOUS HEMODIAFILTRATION 108
- DIALYSIS SERVICES 109
- TABLE 46 HEMODIALYSIS TREATMENT BY PROVIDER TYPE, 1990 - 2009 (%) 109
- FIGURE 24 HEMODIALYSIS TREATMENT BY PROVIDER TYPE, 1990 - 2009 (%) 109
- TABLE 47 U.S. DIALYSIS PROVIDERS, BY TYPE, 2008 110
- TABLE 47 (CONTINUED) 111
- TABLE 47 (CONTINUED) 112
- TABLE 48 MARKET SHARE, HEMODIALYSIS PROVIDERS, 2009 (%) 112
- FIGURE 25 MARKET SHARE, HEMODIALYSIS PROVIDERS (%) 113
- THE U.S. MARKET FOR RENAL REPLACEMENT THERAPIES USED IN TREATING KIDNEY
FAILURE 113
- HEMODIALYSIS FOR TREATING CKD 113
- Hemodialysis for Treating CKD (Continued) 114
- RENAL REPLACEMENT THERAPIES FOR TREATING ARF 115
- TABLE 49 THE U.S. MARKET FOR DIALYSIS THERAPY BY TYPE, THROUGH 2014 ($
MILLION) 115
- FIGURE 26 THE U.S. MARKET FOR DIALYSIS THERAPY BY TYPE, 1996 TO 2014 ($
MILLION) 116
Chapter-7: RENAL RELACEMENT PRODUCTS AND THERAPIES USED IN KIDNEY FAILURE TREATMENT 37
Chapter-8: SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT 12
- VASCULAR ACCESS PROCEDURES 117
- AV FISTULA 117
- FIGURE 27 FOREARM AV FISTULA 118
- AV GRAFT 118
- FIGURE 28 A TYPE OF AV GRAFT 119
- VENOUS CATHETER 119
- FIGURE 29 VENOUS CATHETER 120
- ACCESS REPLACEMENT/REPAIR 120
- VASCULAR ACCESS MARKET BY TYPE 121
- PERITONEAL DIALYSIS CATHETER 122
- FIGURE 30 TENCKHOFF CATHETERS 122
- PD CATHETERIZATION COSTS 122
- KIDNEY TRANSPLANTATION 123
- DECEASED DONORS 123
- LIVING DONORS 123
- THE TRANSPLANT PROCEDURE 124
- Donor 124
- Recipient 124
- Compatibility 125
- Post Surgery 125
- THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN TREATING RENAL FAILURE 126
- THE U.S. MARKET FOR SURGICAL ...(CONTINUED) 127
- TABLE 50 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE
TREATMENT BY TYPE, THROUGH 2014 ($ MILLION) 128
- FIGURE 31 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE
TREATMENT BY TYPE, 1996-2014 ($ MILLION) 128
Chapter-9: THE INTERNATIONAL MARKET 7
- TABLE 54 LEADING PRODUCT AND THERAPY PROVIDERS FOR RENAL FAILURE TREATMENT
IN THE U.S., 2009 136
- PHARMACEUTICALS MANUFACTURERS 137
- DIALYSIS EQUIPMENT MAKERS 137
- MANUFACTURERS OF DIALYSIS CONSUMABLES 138
- THERAPIES 139
- DIALYSIS 139
- SURGERY 140
- UNOS/OPTN 140
COMPANY PROFILES 141
- ABBOTT LABORATORIES 141
- AMAG PHARMACEUTICALS 141
- AMERICAN REGENT INC. 142
- AMERICAN RENAL ASSOCIATES, INC. (ARA) 143
- AMERICAN VASCULAR DIALYSIS ACCESS CENTERS 143
- AMGEN 143
- ASAHI KASEI KURARAY MEDICAL CO. 144
- ASTELLAS PHARMA U.S., INC. 145
- ASTRAZENECA PLC 145
- B.BRAUN MEDICAL INC. 146
- BARD ACCESS SYSTEMS, INC. 146
- BAYER HEALTHCARE 147
- BAXTER INTERNATIONAL 147
- BIOVAIL CORP. 148
- BOEHRINGER INGELHEIM 149
- BRISTOL MYERS SQUIBB COMPANY 149
- CANTEL MEDICAL 150
- CENTERS FOR DIALYSIS CARE 151
- DAVITA, INC. 151
- DIALYSIS CLINIC, INC. (DCI) 151
- DIALYSIS CORP. OF AMERICA (DCA) 152
- DIVERSIFIED SPECIALTY INSTITUTES (DSI) 152
- ELI LILLY AND CO. 153
- FOREST PHARMACEUTICALS 153
- FRESENIUS GROUP 153
- Fresenius Group (Continued) 154
- Renal Solutions, Inc. 155
- GAMBRO AB 155
- GENENTECH INC. 156
- GENZYME CORP. 156
- GLAXOSMITHKLINE PLC 157
- GREENFIELD HEALTH SYSTEMS 157
- INNOVATIVE DIALYSIS SYSTEMS INC. (IDS) 158
- JOHNSON & JOHNSON 158
- KING PHARMACEUTICALS 159
- KIDNEY CENTER, INC. 159
- LIBERTY DIALYSIS 160
- MAQUET CARDIOVASCULAR 160
- MEDCOMP 161
- MEDIGROUP INC. 161
- MEDICINES CO. (THE) 162
- MERCK & CO. 162
- MYLAN BERTEK PHARMACEUTICALS 163
- NAVILYST MEDICAL 163
- NIPRO CORP. 164
- NORTHWEST KIDNEY CENTERS 164
- NOVARTIS PHARMACEUTICALS 165
- NOVO NORDISK A/S 165
- NXSTAGE MEDICAL 166
- PAR PHARMACEUTICAL INC. 166
- PFIZER 167
- PROMETHEUS LABORATORIES INC. 167
- REGIONAL RENAL RESEARCH INSTITUTE (RRI) 168
- RENAL ADVANTAGE, INC. 169
- RENAL VENTURES MANAGEMENT LLC 169
- ROCHE (F. HOFFMANN-LA ROCHE LTD.) 170
- ROCKWELL MEDICAL TECHNOLOGIES 170
- SANOFI-AVENTIS 171
- SATELLITE HEALTHCARE/WELLBOUND 171
- SHIRE PHARMACEUTICALS GROUP 172
- SIGMA-TAU PHARMACEUTICALS 172
- SOLVAY PHARMACETICALS, INC. 173
- TAKEDA PHARMACEUTICALS 173
- TERUMO CORP. 174
- TEVA PHARMACEUTICALS USA 174
- TORAY INDUSTRIES, INC. 175
- TRANSVIVO 175
- UCB 176
- U.S. RENAL CARE, INC. (USRC) 176
- VASCULAR ACCESS CENTERS 177
- WAKE FOREST UNIVERSITY OUTPATIENT DIALYSIS 177
- WATSON PHARMACEUTICALS 178
- WYETH 178
- XCORPOREAL, INC. 179
APPENDIX 180
- TABLE 55 TOP 50 U.S. HOSPITALS FOR RENAL DISORDERS 180
- TABLE 55 (CONTINUED) 181
- TABLE 56 U.S. KIDNEY TRANSPLANT CENTERS, 2006 181
- TABLE 56 (CONTINUED) 182
- TABLE 56 (CONTINUED) 183
- TABLE 56 (CONTINUED) 184
- TABLE 56 (CONTINUED) 185
- TABLE 56 (CONTINUED) 186
- TABLE 56 (CONTINUED) 187
|
 |
